Cancer Vaccines
Largest cervical cancer vaccine efficacy trial shows Cervarix provides excellent protection against lesions caused by most common cancer-causing virus types
Published in Vaccine Weekly, July 18th, 2007
Results from an interim analysis of a Phase III study show that CervarixTM, the GlaxoSmithKline (GSK) cervical cancer candidate vaccine, provides up to 100 percent protection against advanced precancerous lesions caused by the most common types of human papillomavirus, types 16 and 18. The study also strengthens earlier preliminary evidence that the vaccine provides significant protection against infection with additional cancer-causing virus types. These results were published today in The Lancet.
"This landmark trial has provided important new insights into the natural history of cervical lesions, and helps us to more clearly understand the causal link between these...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2007-07-18)
More Articles from Vaccine Weekly
- Bioethics
Case study: cross-cultural bioethics training program helps fight African 'brain drain' - Cancer Vaccines
From clinical cancer research: rethinking therapeutic cancer vaccine trials - Cancer Vaccines
Harnessing the power of the immune system to fight cancer - Cancer Vaccines
Human antibodies that block human and animal SARS viruses identified - Cancer Gene Therapy
Introgen Receives Broad U.S. Patent for Improved Storage-Stable Formulations of its Adenoviral-Based Pharmaceuticals - Cancer Vaccines
Moffitt Studies the Effects of the Immune System on Cancer - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
